The FDA issued a draft guidance Thursday to tackle some of the practical and ethical challenges of using placebos and blinding in clinical trials testing therapies for hematological malignancies and other cancers. The draft recommends placebo-controlled designs only in selected circumstances, such as when surveillance is the standard of care or when the trial uses an add-on design.